Treatment access

Rationalising the paediatric antiretroviral formulary in Malawi

New ARV prescribing guidelines for London (2014)

Global update: hepatitis C treatment activism

Activists protest the price of sofosbuvir: “So-Valdi, So-Expensive” – UK access already rationed

FDA approvals of generic ARVS

Dolutegravir approved in Europe

BMS to add atazanavir to Patent Pool

Donors pledge $12 billion to Global Fund for 2014–2016: increase still short of $15 billion goal

Global Fund and UNAIDS urge Nigeria to reconsider new anti-gay law

Obama increases US contribution to Global Fund to $5 billion over three years

HIV struggle in South Africa undermined by medicine stockouts and mismanagement

Southern African treatment guidelines retain CD4 threshold of 350 for starting ART (2013)

High prices for antiretrovirals in middle-income countries outside Africa

From sky high to CHAI* – what needs to be done about dolutegravir pricing?

UK pledges £1 billion for Global Fund

France pledges $1.4 billion for Global Fund

UNAIDS reports new HIV infections are reduced by one-third compared to 2001

WHO 2013 guidelines: what about the missing formulations?

Pipeline oral HCV drugs and generic global access to DAAs: the need to mirror ARV programmes

Ending global use of d4T: UNITAID to tip market to safer alternatives

TRIPS extension for least developed countries

Community request Gilead to study and develop separate formulation of new tenofovir prodrug

Upcoming WHO ART guidelines (2013)

Fixed dose combination efavirenz/tenofovir/FTC for South Africa

New UNAIDS report highlights progress in the AIDS response in Africa

Indian Supreme Court delivers verdict in Novartis case: decision safeguards access to affordable medicines and prevents abusive patenting of medicines

FDA approval of generic ARVs

New UNITAID grants focus on paediatric HIV, TB and malaria

Global Fund results continue upward trend

Germany extends €200 million annual support to Global Fund until 2016

New analysis of country pledges and contributions to the Global Fund

Renewal of Indian Global Fund Grant made conditional on government funding for ART

MSF and DNDi report highlights importance of research into neglected diseases

FDA approval of generic ARVs

d4T – time to move on

Global Fund provides ART for 4.2 million people: 2012 update

$84 million grant to Zimbabwe to reach universal access in 2012

Mark Dybul to be the next executive director of the Global Fund

US NIH to enforce open access to clincal trial results

FDA approval of generic ARVs

Free HIV treatment in the UK for all, irrespective of residency status

Robin Hood Tax begins in France

Novartis case enters Indian Supreme court

Online video interviews between researchers and activists

India: Bayer stay order against compulsory licence denied

IAS: social and political talks online as web casts

FDA approval of generic ARVs

Activists protest at IAS for Global Fund to stick to principles

EU parliament rejects anti-counterfeiting trade agreement: allows continued access to generic medicines

US trade deal threatens access to medicines

Stavudine (d4T) phase-out festival in Delhi

FDA approval of generic ARVs: nevirapine and Combivir now off-patent in the US

Global action over the challenge to India

Why global health activists are fired up about Novartis

Obama’s global, domestic & HIV research budget backslides on existing commitments

FDA approval of generic ARVs

Disastrous warning for global HIV programmes in 2012

Janssen block Patent Pool access to darunavir, rilpivirine and etravrine

UNITAID continues funding the Patent Pool, paediatric HIV medicines and malaria

Michel Kazatchkine resigns from Global Fund: Gabriel Jaramillo, Brazilian banker, to serve as general manager

Call to Action on Global Fund restriction to new funding to 2014

Analysis of why the Global Fund cancelled Round 11

Reaction to the Global Fund's decisions on Round 11 and grant renewals

Activists oppose Gates Foundation funding study using low dose d4T

Global Fund cancels Round 11 and introduces new rules for grant renewals

Post navigation